Successful growth hormone (GH) therapy is contingent on patient adherence. Saizen® (somatropin), with its unique selection of eHealth tools, helps you help your patients stick to their individual treatment plans.
The easypodTM system gathers real-time injection data to help you monitor your patients’ treatment, improving adherence and consequently treatment outcomes.1 easypodTM injection pen provides a wide range of doses, allowing you to tailor GH treatment to each individual patient – no matter the indication. Store the unused Saizen cartridge in a refrigerator (2°C-8°C). Do not freeze. Store in the original package to protect from light. After first injection, the Saizen cartridge or the easypod auto-injector containing the Saizen cartridge has to be stored in a refrigerator (2°C-8°C) for a maximum of 28 days, of which up to 7 days can be outside of a refrigerator at or below 25°C. When stored outside of the refrigerator for up to 7 days, the Saizen cartridge must be returned to the refrigerator and used within 28 days after first injection.2
How Saizen® Works
The active ingredient of Saizen® is a human GH produced by recombinant DNA technology (r-hGH) with an amino acid sequence, structure, and pharmacokinetic profile identical to the dominant form of endogenous human GH. Pharmacokinetic parameters do not appear to differ between males and females, or between adults and children.2
Saizen® binds to receptors in target tissues in the same manner as endogenous GH, thus exerting a range of anabolic and growth-promoting effects.2*
The treatment has a long-lasting pharmacodynamic effect, with serum IGF-1 levels in healthy volunteers peaking 12 hours after a 5 mg s.c. dose, and remaining elevated for 24 hours after dosing. Daily Saizen® administration is not expected to result in accumulation; bioavailability of Saizen® after s.c. and i.m. administration is 70–90 percent, and time to reach maximum concentration after s.c. injection is 3–5 hours.3
Saizen® in various formulations was generally well tolerated in healthy volunteers. Any adverse events were consistent in both nature and severity with the known safety profile of r-hGH.3
* No in vitro pharmacology studies are available to support the clinical indications of Saizen®. In addition, no in vivo pharmacology studies have been conducted with r-hGH. However, considering that the molecular structure of r-hGH is identical to that of human pituitary GH (p-hGH) in terms of amino acid sequence and structure, r-hGH is expected to display identical pharmacological properties.
BUY SAIZEN
